B-295 Lower Tacrolimus Trough Levels as a Predictor of Antibody-Mediated Rejection in Kidney Transplant Patients

Cody W. Lewis; Ahmed Mostafa; Fang Wu; Jing Liu

doi:10.1093/clinchem/hvaf086.682

October 1, 2025Clinical ChemistryOpen Access

B-295 Lower Tacrolimus Trough Levels as a Predictor of Antibody-Mediated Rejection in Kidney Transplant Patients

View Full Paper

Ask AI

Bookmark

Share

Key Points

Patients who developed antibody-mediated rejection had significantly lower tacrolimus levels in the months preceding rejection.
Of 329 kidney transplant patients, 32 developed antibody-mediated rejection while 90 developed cell-mediated rejection over the study period.
Statistical analysis revealed no significant difference in tacrolimus levels during the first year, but indicates a potential predictive value for monitoring.
These findings suggest tracking tacrolimus levels could enhance the evaluation of transplant success and reduce risks associated with rejection.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis shows lower tacrolimus levels correlate with antibody-mediated rejection in kidney transplant patients, suggesting a need for monitoring immunosuppressive drug levels.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lewis et al. (2025) studied this question.

synapsesocial.com/papers/68e040e9a99c246f578b308a https://doi.org/10.1093/clinchem/hvaf086.682

View Full Paper

Ask AI

Bookmark

Share

B-295 Lower Tacrolimus Trough Levels as a Predictor of Antibody-Mediated Rejection in Kidney Transplant Patients

Key Points

No abstract yet

Implication

Discussion

Cite This Study

B-295 Lower Tacrolimus Trough Levels as a Predictor of Antibody-Mediated Rejection in Kidney Transplant Patients

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading